Send-Out Versus In-House Vitamin D Testing
Your 210-bed community hospital laboratory sends out 25-hydroxyvitamin D: 240 tests per month at a send-out charge of $16.40 per test; the hospital is reimbursed $21.00. The chemistry supervisor proposes bringing the test in-house. Reagent is $4.85 per test, direct labor $2.15, and consumables $0.75. A reagent-rental analyzer would cost $900 per month, service $380 per month, and additional QC materials $200 per month. Validation, training, and interface build would consume $3,200 of one-time operating expense and about 60 hours of staff time. The analyzer lease is 18 months and cannot be cancelled. The laboratory has bench space and two technologists who could be cross-trained. The CFO asks for a recommendation before the capital committee meeting next week.
1. Calculate the monthly financial impact, break-even volume, and payback of bringing the test in-house. What do you recommend?
Read the worked answer
Calculation
- In-house variable cost = $4.85 + $2.15 + $0.75 = $7.75/test.
- Fixed monthly = $900 + $380 + $200 = $1,480.
- In-house monthly = 240 × $7.75 + $1,480 = $1,860 + $1,480 = $3,340.
- Send-out monthly = 240 × $16.40 = $3,936.
- Monthly savings = $596 ($7,152/year).
- Break-even = $1,480 / ($16.40 − $7.75) = $1,480 / $8.65 = 171.1, so 172 tests/month.
- Payback = $3,200 / $596 = 5.4 months.
Recommendation Proceed only if volume is expected to stay above roughly 200/month and the 60 staff hours can be absorbed. The margin is real but thin: a 20% volume drop to 192/month still clears break-even but leaves only about $180/month and pushes payback to about 18 months. Negotiate the analyzer lease and validation support before signing.
2. The send-out vendor offers a 10% rate reduction if the hospital signs a 24-month contract. How does that change the decision, and what nonfinancial factors should influence it?
Read the worked answer
A 10% reduction gives $14.76/test. Monthly send-out = 240 × $14.76 = $3,542.40, a saving of $393.60/month versus the current send-out cost. That is $202/month less attractive than the in-house case, so the financial advantage becomes marginal.
Nonfinancial factors: same-day turnaround versus 3–5 days; clinician satisfaction; control of add-on testing; ability to place other assays on the analyzer; staff cross-training; proficiency testing and validation burden; the 18-month lease lock-in; and the 24-month vendor contract, which protects price but reduces flexibility. Use the vendor offer as leverage: if the lease can be shortened or the per-test cost lowered, proceed in-house; otherwise the 10% discount is a defensible fallback.
3. Volume is uncertain: the new endocrinologist may increase orders by 15%, or utilization management may cut them by 20%. How would you frame the decision for the CFO?
Read the worked answer
Run three scenarios: 192, 240, and 276 tests/month.
- At 192: 192 × $8.65 − $1,480 = $180.80/month; payback about 18 months.
- At 240: $596/month; payback 5.4 months.
- At 276: 276 × $8.65 − $1,480 = $907.40/month.
Frame the decision as a bet on clinician behavior and volume, not a fixed cost saving. Present a decision rule: proceed if the endocrinologist commits to ordering and if utilization management has no active restriction; otherwise take the vendor discount or negotiate a trial. Include a downside trigger: if volume falls below 172 for two consecutive months, revisit the decision. Ask for a 12-month lease or a per-test cap to limit the downside.